Lar»New iRhythm data supports the use of long-term ambulatory cardiac monitoring
BySean Whooley
iRhythm(Nasdaq:IRTC) today announced the release of four studies that strengthen the evidence behind its long-term cardiac monitoring.
San Francisco-based iRhythm presented the data at the Heart Rhythm Society's annual meeting, Heart Rhythm 2023, in New Orleans. The data supports ambulatory cardiac monitoring for up to 14 days with the company's Zio XT. It has demonstrated higher diagnostic yield and better diagnostic accuracy of ventricular arrhythmias in a variety of patient populations.
"These studies thematically demonstrate the value of iRhythm's Zio products and services – particularly in identifying ventricular arrhythmias for risk stratification and disease management,"thesedr. Mintu Turakhia, iRhythm's Chief Medical Officer, Chief Scientific Officer and Executive Vice President of Product Innovation. "The results have important clinical and scientific implications and further demonstrate the power of our technology across the full range of clinical arrhythmias."
Extended ambulatory ECG monitoring
iRhythm's first study, the EXAMINE-HCM study, evaluated patients with hypertrophic cardiomyopathy (HCM). He found that long-term monitoring of up to 14 days with Zio XT significantly improves the diagnostic yield of non-sustained ventricular tachycardia (NSVT).
Key outcomes included 48 hours of monitoring, in which nearly two-thirds of patients with high-risk NSVT episodes were absent. May affect risk stratification and treatment.
iRhythm showed a diagnostic yield of 18% for detecting NSVT in the first 48 hours. He observed 48% at 14 days, with 63% of first NSVT episodes occurring after the first 48 hours.
The company saw an 8% diagnostic yield in detecting high-risk NSVT episodes within the first 48 hours. This compared to 24% after 14 days, with 64% of the first high-risk NSVT runs occurring after the first 48 hours.
iRhythm premature ventricular contractions (PVC) strain analysis
The company performed a PVC burden analysis of 106,705 patients. It showed the association of increased monitoring for at least 7 to 10 days duration with greater accuracy in categorizing patients by PVC burden level.
iRhythm says the important findings show how misclassification can affect clinical decision-making.
An estimate of 48 hours of PVC misclassified PVC burden compared with 14 days of ambulatory ECG monitoring. At least seven days of continuous ambulatory ECG monitoring (performed by Zio) were required to achieve greater than 95% accuracy in load categorization.
Practical variation after NSVT ECG detection
A retrospective Veterans Health Administration study evaluated 58,279 patients. One-third of patients who received long-term ambulatory ECG monitoring for up to 14 days with Zio had NSVT.
iRhythm said the findings highlight an opportunity to create risk models and integrated treatment pathways after ECG monitoring.
The study observed wide variation at the site level in diagnostic testing and treatment across the VA health system following detection of NSVT. It included the proportion of patients with an echocardiogram, coronary angiography, exercise test, cardiology care and use of cardiovascular medications in the 90 days after outpatient follow-up.
Evaluation of flecainide in arrhythmogenic right ventricular cardiomyopathy (ARVC)
iRhythm conducted the Flec-ARVC study at the University of Rochester, the Johns Hopkins ARVC Program and other external institutions.
The company said it marks the first randomized clinical trial evaluating flecainide in ARVC. iRhythm said that using the Zio services highlights its PVC load measurement capabilities and its capabilities in clinical trials and research.
In the randomized, placebo-controlled crossover study of 41 patients receiving the Zio XT service for seven days, flecainide significantly reduced the CVP burden.
In case you lost
- Analysts Still Bullish On Insulet Despite Medtronic's EOFlow Purchase, Stock Market Backlash
- The Best Innovations in Cardiac Care at Heart Rhythm 2023
- FDA approves Zoll therapy for sleep apnea with MRI
- Boston Scientific will not purchase the majority interest in M.I. technology
- Convatec, Beta Bionic's partner in the iLet Bionic Pancreas
- HeartBeam wins AI-related patent for handheld vector ECG
- Medtronic shares fall on lower growth forecasts
- Medtronic buys portable insulin patch maker EOFlow for DKK 738 million. USD
- Fast Five: Boston Scientific adds 400 jobs in Ireland, ICU Medical recalls some infusion pump batteries
- ClearPoint Neuro enters into a drug delivery license agreement with UCB
- Research supports Onward's brain-computer interface technology
- Artelon raises $20 million to treat joint instability
- Aerami presents positive data for the treatment of inhaled pulmonary hypertension
- Artivion Gets FDA Approval for PerClot, Initiates Transfer to Baxter
- Stryker Announces First Completed Cases With Brain Surgery Guidance Platform
- Abbott CardioMEMS sensor nearly cuts hospitalizations for heart failure by half, study finds
- Masimo Expands HEOS Home Surveillance Platform
Fra Medical Design & Outsourcing
- Stratasys and Desktop Metal plan $1.8 billion merger
Stratasys (Nasdaq:SSYS) and Desktop Metal (NYSE:DM) plan to combine in a $1.8 billion equity transaction, the 3D printing companies said today. The companies estimate they will generate $1.1 billion in revenue in 2025 after the merger and said they expect the additive manufacturing industry to grow to $100 billion by 2032. Stratasys and Desktop Metal both… […]
- What's New in 3D Printing: Medical Devices, Research, Innovation, Automation, and Partnerships
3D printing is helping more patients than ever before through personalized medical devices, faster and cheaper prototyping and more accessible manufacturing. Recent developments include research on tissue and organ regeneration, rapid responses to supply chain shortages, wearable devices that improve patient care, and large investments by device manufacturers. Here are some of the advances in 3D printing… […]
- A Times Microwave Systems lança o cabo microcoaxial XtendedFlex 045
NEWS RELEASE: Times Microwave Systems Introduces XtendedFlex 045 Microcoaxial Cable New Addition to the XtendedFlex™ Product Line Delivers Unmatched Compactness and Flexibility in a Low-Loss Design for Precision Medical Devices and More WALLINGFORD, CT — Times Microwave Systems , the innovative brand of microwave, cable and plug interconnect sets, announced the launch of... […]
- Acquisition of Ossis by Zimmer Biomet Expands Bio-Gate's Reach
PRESS RELEASE: Bio-Gate and OSSIS Expand into Additional International Markets with HyProtect™ Coatings on Compassionate Care Implants. Stronger and expanded international market access for OSSIS following acquisition of Zimmer Biomet Increased awareness of HyProtect™ coatings Increased volume of implants coated with HyProtect™ Nuremberg/Bremen – Bio-Gate AG (ISIN DE000BGAG981), a leading supplier of innovative and individual technologies … [. ..]
- How entity founders can find a buyer for their medical technology
If you are a medical technology entrepreneur looking to sell your medical device business, Frank Jaskulke is a good contact to have in your network. He is Deputy Chief Intelligence Officer at Medical Alley and head of the Medical Alley Starts program, which provides resources and support for healthcare startups. His Minnesota-focused organization has worked with more than… […]
(Video) RX-1 Mini Patch Monitor - 3D printed wearable sweat sensor can promote home monitoring
Researchers at the University of Hawaii at Mānoa College of Engineering say they have developed a 3D-printed wearable sweat sensor. Dubbed the "swetainer", the device harnesses the power of additive manufacturing to enable a new type of wearable sweat sensor. The researchers say the small, handheld device - about the size of a child's sticker -... […]
- MedAccred joins the Irradiation Panel
NEWS ANNOUNCEMENT: MedAccred Program Joins Influential Irradiation Industry Association. The panel is made up of suppliers and users of irradiated products and irradiation services, regulatory bodies and consultants. The membership currently consists of… […]
- Mexico's Ministry of Health updates rules and requirements for classifying medical devices
Ana Karen Hidalgo Rodríguez, Emergo Group. Continuing our updates on the recently released 5.0 edition of the Medical Devices Supplement to the Mexican Pharmacopoeia (hereinafter: Pharmacopoeia), we discuss the classification rules related to medical devices. Classification of medical devices based on their risk level Annex II of the Mexican Pharmacopoeia includes … […]
- Times Microwave Systems launches new microcoaxial cable
Times Microwave Systems today announced the release of its new TF-047 microcoaxial cable for high performance and reliability in a compact size. Times Microwave Systems, based in Wallingford, Connecticut, designed the TF-047 as a versatile SwaP-C solution with extensive connectivity options. Its compact, flexible design allows for easy routing in areas with limited space. The cable has a total diameter … […]
- These smart implant coatings watch for implant failure while killing bacteria
University of Illinois researchers have developed "smart" coatings for orthopedic implants that can monitor stress on the devices. These coatings monitor stress to provide early warning of implant failure while killing infection-causing bacteria. They integrate flexible sensors with a nanostructured antibacterial surface. Scientists say they received inspiration for the surface of the wings of … […]
- Tips and Warnings to Help You Choose a Medical Technology Contract Manufacturer
A few years ago, Vivasure Medical faced an emergency that "almost brought our business to a standstill," said co-founder Gerard Brett. “We chose a bona fide supplier – it looked like they had what it took to do the job for us,” he said. “We were working on developing part of our product and... […]
AboutSean Whooley
Sean Whooley is an associate editor who produces work primarily for MassDevice, Medical Design & Outsourcing, and Drug Delivery Business News. He earned a degree in cross-platform journalism from the University of Maryland, College Park. You can connect with him atLinkedInor email swhooley@wtwhmedia.com.
FAQs
What is the new product of iRhythm? ›
May 25, 2021 — iRhythm Technologies Inc. announced two new U.S. Food and Drug Administration (FDA) 510(k) clearances — one for a new and improved design of its flagship Zio wearable cardiac monitor, and a second for updated artificial intelligence (AI) capabilities.
What is ambulatory cardiac monitoring? ›Ambulatory monitors are devices that record the electrical activity in your heart. These are used to detect heart rhythm problems over a longer period of time, and you can take them home with you. They're an invaluable tool when it comes to diagnosing problems that happen unpredictably and outside of a medical setting.
What are the two most common types of ambulatory monitoring? ›Ambulatory EKG monitoring allows your healthcare providers to monitor your EKG over a period of time, while you're going about regular activities. There are two common types of ambulatory monitors — Holter monitors and ambulatory telemetry monitors (ATMs).
What is the purpose of continuous cardiac monitoring? ›To monitor your heart after a heart attack or when starting or stopping a heart medicine. To check if a pacemaker or an implantable cardioverter-defibrillator is working properly. To look for the cause of a stroke when the cause cannot be easily found with other tests.
Is iRhythm FDA approved? ›iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System.
Is iRhythm a good company? ›Is iRhythm Technologies a good company to work for? iRhythm Technologies has an overall rating of 3.4 out of 5, based on over 191 reviews left anonymously by employees. 51% of employees would recommend working at iRhythm Technologies to a friend and 54% have a positive outlook for the business.
What is an advantage of ambulatory ECG monitoring? ›Ambulatory ECG monitoring for longer periods (when compared with standard ECG for a 10-second time period) is more sensitive for detecting spontaneous, often highly variable cardiac arrhythmias or conduction abnormalities [1,2].
What is the most common cardiac test done in ambulatory care? ›Ambulatory electrocardiography (ECG) monitors are often used to detect cardiac arrhythmia. For patients with symptoms, an external cardiac loop recorder will often be recommended.
What are the most common ambulatory cardiology procedures? ›Some of the most common procedures being performed at the Banner Cardiovascular Center include placement of pacemakers, loop recorders and AICD implants, heart catheterizations and stenting.
Which of the following devices should a patient avoid while wearing an ambulatory monitor? ›Certain devices can interrupt the signal from the electrodes and distort your Holter monitor test results. Stay away from microwaves, electric blankets, electric toothbrushes, electric razors, and metal detectors.
Which is the most common type of cardiac monitoring in the hospital setting? ›
The ECG is the most widely used initial diagnostic test because it is ubiquitous, noninvasive, and inexpensive, and provides vital information about cardiac rhythm, presence of arrhythmias, myocardial ischemia/infarction, and other abnormalities.
What responsibilities might you have for ambulatory monitoring? ›What responsibilities might you have for ambulatory monitoring? You will be responsible for applying and removing the ambulatory monitor,providing patient education, and ensuring that the results are placed in the patient's chart.
Who needs continuous cardiac monitoring? ›Continuous monitoring for changes in heart rhythm with cardiac telemetry is recommended for all patients admitted to an intensive care unit (ICU).
Who needs a cardiac monitor? ›A health care provider may recommend a Holter monitor if you have: Signs and symptoms of an irregular heart rhythm (arrhythmia) Unexplained fainting. A heart condition that increases the risk of arrhythmias.
Does a cardiac event monitor record all the time? ›An event monitor does not record continuously. Instead, it records when you activate it. Some event monitors will automatically start recording if an abnormal heart rhythm is detected. Event monitors can be worn for a month or longer.
Who is iRhythm owned by? ›iRhythm Technologies Inc (NASDAQ:IRTC)
Institutional investors hold a majority ownership of IRTC through the 110.93% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Medical Specialties industry.
- Preventice Solutions.
- Bardy Diagnostics.
- Byteflies.
- Peerbridge Health.
- LIVMOR.
- AliveCor.
- SEERS Technology.
- Wellysis.
For cardiac monitor usage between seven to 15 days, the main code used by iRhythm, Novitas set the reimbursement rate at roughly $233, up from the $115 rate set in April. The rate for monitoring between 48 hours and 7 days was also set at $223, up from $103.
How much does a Director at iRhythm make? ›$362,695. The estimated total pay for a Director at iRhythm Technologies is $362,695 per year.
How long has iRhythm been in business? ›More about iRhythm
Founded in 2008, the San Francisco–based company seeks to usurp the old-school Holter monitor for electrocardiograph monitoring and AFib detection.
Is Zio patch better than heart monitor? ›
A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours. The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device.
Why would you have to wear a heart monitor for 30 days? ›A 30-Day Event Monitor is a small portable device that records the electrical activity of the heart for 30 days. This monitor is very helpful to the physician in diagnosing various abnormal heart rhythms and medical conditions. An event monitor does not record continuously.
What is the difference between an ECG and an ambulatory ECG? ›An ECG recording machine will usually show your heart rhythm and electrical activity as a graph displayed electronically or printed on paper. For an ambulatory ECG, the ECG machine will store the information about your heart electronically, which can be accessed by a doctor when the test is complete.
What is a 24 hour ambulatory ECG called? ›What is a Holter monitor? The Holter monitor is a type of portable electrocardiogram (ECG). It records the electrical activity of the heart continuously over 24 hours or longer while you are away from the doctor's office.
What is the best test to check for clogged arteries? ›A coronary angiogram is a type of X-ray used to examine the coronary arteries supplying blood to your heart muscle. It's considered to be the best method of diagnosing coronary artery disease - conditions that affect the arteries surrounding the heart.
Does an echocardiogram show blockages? ›This part of the test measures the speed and direction of blood flow within the heart and vessels. It can help show blocked or leaking valves and check blood pressure in the heart arteries.
What is the best test to check heart health? ›Echocardiogram (ultrasound)
An echocardiogram is a common test. It gives a picture of your heart using ultrasound, a type of X-ray.
Get the latest on healthcare leadership in your inbox.
According to the ECRI Institute PSO (patient safety organization) report, the top four risks for patient safety at ambulatory care settings are diagnostic testing errors, medication events, falls, and security incidents.
Cardiac Center
Open heart procedures, which represent a major portion of our volume, require cardiopulmonary bypass (heart-lung bypass machine) and are usually the most complicated and complex procedures.
Coronary artery bypass graft surgery (CABG), also called coronary artery bypass, coronary bypass or bypass surgery, is the most common type of heart surgery. More than 300,000 people have successful bypass surgery in the United States each year.
What is an alternative to ambulatory blood pressure monitoring? ›
Frequent self-measurements of BP using simple home BP recorders which you can purchase from a pharmacy can be a very good alternative to Ambulatory BP testing.
How do you sleep with an ambulatory blood pressure monitor? ›If asked, you will need to keep the monitor on throughout the night; many people put the machine under the pillow or on the bed while they sleep. At the end of the monitoring period you can remove the machine and cuff and give it back to the hospital or surgery.
What are contraindications to ambulatory monitoring? ›When is it contraindicated? Ambulatory electrocardiographic monitoring is contraindicated if it will delay appropriate hospitalisation or a more appropriate procedure. For example, AECG should not be part of the initial investigation of intermittent stable angina; a stress test would be more appropriate.
What is the most common lead utilized for cardiac monitoring? ›The most commonly used lead is lead II - a bipolar lead with electrodes on the right arm and left leg. This is the most useful lead for detecting cardiac arrhythmias as it lies close to the cardiac axis (the overall direction of electrical movement) and allows the best view of P and R waves.
What is the difference between cardiac monitoring and telemetry monitoring? ›Unlike bedside heart monitors that restrict your movement, telemetry systems are portable. You can wear a telemetry device using a cloth holder, which allows you to move about.
How long does an ambulatory monitor typically record an ECG? ›Ambulatory ECG equipment
These recorders are typically used for 24 or 48 hours to record events which might reasonably be expected to occur within that timeframe, ie frequent, or at least once a day symptoms.
What factors can affect the results of ambulatory monitoring? Answer: Improper lead attachment, incomplete patient diary, and failure of the patient to maintain a normal routine.
What are the limitations of ambulatory blood pressure monitoring? ›The limitations of ambulatory blood pressure monitoring include potential discomfort during nighttime periods, the reluctance of some patients to undergo ambulatory blood pressure monitoring especially for repeat measurement, occasionally not being able to detect genuine artefactual measurements, and the limited ...
How much does it cost to wear a heart monitor for 30 days? ›However, outpatient cardiac event monitors are commonly reimbursed on a 30-day basis. The cost of 30 days of outpatient cardiac monitoring ranges from $284 to $783 with an average of $532.
Do all hospital patients need cardiac telemetry? ›Continuous monitoring for changes in heart rhythm with cardi- ac telemetry is recommended for all patients admitted to an intensive care unit (ICU).
How many patients can a cardiac monitor tech watch? ›
Each monitor technician observes up to 40 patients, watching for changes to the patient's cardiac status. For the pulmonary step-down unit, the technicians monitor SpO2, heart rate, and cardiac rhythm.
What is the average cost of a cardiac monitor? ›On MDsave, the cost of a Cardiac Device Monitoring ranges from $120 to $157. Those on high deductible health plans or without insurance can shop, compare prices and save. Read more about how MDsave works.
Do I really need a heart monitor? ›Do I need a heart rate monitor? No, it's not required that you bring a heart rate monitor into your workout routine. You can maintain an active, healthy lifestyle filled with exercise without one. What it comes down to is what information is important to you, especially during your workouts.
Why does my doctor want me to wear a heart monitor? ›Your doctor may recommend that you wear a monitor if you have been experiencing symptoms such as chest pain, shortness of breath or racing heartbeat, or simply if you are taking a new medication that could affect your heart.
What is the compensation for iRhythm? ›| Job Title | Median Total Salary |
|---|---|
| Hardware Engineer Salary | $116,620 |
| Product Designer Salary | $154,770 |
| Sales Salary | $198,990 |
| Software Engineer Salary | $255,000 |
iRhythm Technologies Inc (NASDAQ:IRTC)
The 9 analysts offering 12-month price forecasts for iRhythm Technologies Inc have a median target of 150.00, with a high estimate of 170.00 and a low estimate of 130.00. The median estimate represents a +15.17% increase from the last price of 130.24.
IRhythm Technologies Biotelemetry Acquired By Goliath Philips.